Scarica l'app Stockscreener
175.97
3.35%
5.70
Dopo l'orario di chiusura:
177.00
1.03
+0.59%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$170.27
Aprire:
$185.02
Volume 24 ore:
5.36M
Relative Volume:
1.90
Capitalizzazione di mercato:
$37.53B
Reddito:
$447.02M
Utile/perdita netta:
$-1.18B
Rapporto P/E:
-28.47
EPS:
-6.1812
Flusso di cassa netto:
$-906.14M
1 W Prestazione:
-0.65%
1M Prestazione:
-9.37%
6M Prestazione:
+82.41%
1 anno Prestazione:
+167.76%
Intervallo 1D:
$169.00
$186.19
Intervallo di 1 settimana:
$167.39
$186.19
Portata 52W:
$60.40
$212.75
Insmed Inc Stock (INSM) Company Profile
Nome
Insmed Inc
Settore
Industria
Telefono
908-977-9900
Indirizzo
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Confronta INSM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-19 | Ripresa | Truist | Buy |
| 2025-12-04 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-10-28 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-08-20 | Iniziato | William Blair | Outperform |
| 2025-08-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Iniziato | Jefferies | Buy |
| 2025-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-04-23 | Iniziato | Truist | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-07-26 | Iniziato | Guggenheim | Buy |
| 2022-12-09 | Iniziato | Mizuho | Buy |
| 2022-12-07 | Iniziato | Barclays | Overweight |
| 2022-11-18 | Iniziato | BofA Securities | Buy |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2021-12-06 | Iniziato | JP Morgan | Overweight |
| 2021-10-19 | Ripresa | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-10-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-10-12 | Ripresa | Stifel | Buy |
| 2019-09-03 | Iniziato | Goldman | Buy |
| 2019-04-09 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-15 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-01-02 | Iniziato | Canaccord Genuity | Buy |
| 2018-08-06 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Iniziato | Goldman | Neutral |
| 2018-04-23 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Iniziato | Morgan Stanley | Overweight |
| 2018-01-18 | Iniziato | Credit Suisse | Neutral |
| 2017-09-05 | Reiterato | Evercore ISI | Outperform |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-07-11 | Iniziato | Robert W. Baird | Outperform |
| 2016-03-15 | Iniziato | Stifel | Buy |
| 2015-11-09 | Downgrade | UBS | Buy → Neutral |
| 2015-10-06 | Reiterato | H.C. Wainwright | Buy |
| 2015-06-09 | Iniziato | Citigroup | Neutral |
| 2014-03-26 | Reiterato | HC Wainwright | Buy |
Mostra tutto
Insmed Inc Borsa (INSM) Ultime notizie
Is It Too Late To Reassess Insmed (INSM) After Its Huge Share Price Surge? - Yahoo Finance
The Bull Case For Insmed (INSM) Could Change Following Bold 2025 Revenue Guidance HikeLearn Why - Yahoo Finance
What risks investors should watch in Insmed Incorporated stockJuly 2025 Momentum & Low Volatility Stock Suggestions - ulpravda.ru
Tangible book value per share of Insmed Incorporated – BX:IM8N - TradingView — Track All Markets
Healthcare dealmakers head to San Francisco hoping for megamergers in 2026 - Reuters
Insmed (INSM) Surpasses Revenue Expectations with Strong Growth - GuruFocus
Insmed Maps Aggressive 2026: New Lung Disease Drug, Pipeline AdvancesInsmed (NASDAQ:INSM) - Benzinga
Insmed posts early 2025 revenue beating consensus (INSM:NASDAQ) - Seeking Alpha
Insmed: Strong Brinsupri Launch, Solid Arikayce Performance, and 2026 Catalysts Underpin Buy Rating - TipRanks
Insmed jumps after forecasting preliminary 2025 revenue above estimates - TradingView — Track All Markets
Insmed Incorporated Provides Revenue Guidance for the Full Year 2025 - MarketScreener
Insmed shares jump on robust BRINSUPRI rollout and ARIKAYCE outperformance - MSN
Insmed (INSM) Projects Arikayce Revenue of $450M-$470M for FY26 - GuruFocus
INSM Projects Brinsupri Revenue to Reach $172.7 Million by FY25 - GuruFocus
Insmed stock rises after strong BRINSUPRI launch, ARIKAYCE revenue beat By Investing.com - Investing.com UK
Insmed reports strong Q4 revenue for BRINSUPRI and ARIKAYCE By Investing.com - Investing.com UK
Insmed Inc Provides Business Update at J.P. Morgan Healthcare Conference - TradingView — Track All Markets
Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference - PR Newswire
Insmed’s ‘ginormous’ lung drug sales; J&J’s US pricing deal - Yahoo Finance
Can Insmed Incorporated stock deliver consistent earnings growth2025 Analyst Calls & Short-Term High Return Ideas - ulpravda.ru
Why Insmed Incorporated (IM8N) stock remains top rated2025 Dividend Review & Precise Swing Trade Alerts - ulpravda.ru
Insmed chief legal officer Smith sells $549k in stock By Investing.com - Investing.com Canada
Insmed chief medical officer Flammer sells $2.8m in stock By Investing.com - Investing.com Canada
Insmed chief medical officer Flammer sells $2.8m in stock - Investing.com
Insmed CFO Bonstein sells $808,733 in stock By Investing.com - Investing.com Australia
Insmed COO Adsett sells $747k in stock By Investing.com - Investing.com Canada
Insmed CFO Bonstein sells $808,733 in stock - Investing.com
INSMED Executives Conduct Series of Stock Transactions - TradingView — Track All Markets
Insmed Insider Sold Shares Worth $549,494, According to a Recent SEC Filing - MarketScreener
INSMED Chief Legal Officer Sells Shares - TradingView — Track All Markets
Published on: 2026-01-09 00:10:22 - ulpravda.ru
Analysis Recap: Is Insmed Incorporated stock a good choice for value investors2025 Fundamental Recap & AI Powered Market Entry Strategies - ulpravda.ru
Will Insmed Incorporated stock outperform tech sector in 20252025 Market Outlook & Real-Time Stock Price Movement Reports - ulpravda.ru
Will Insmed Incorporated stock recover faster than peersJuly 2025 Summary & Long-Term Investment Growth Plans - ulpravda.ru
Published on: 2026-01-08 19:10:10 - ulpravda.ru
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed IncorporatedINSM - PR Newswire
Jim Cramer on Insmed: "This One Is Worth Keeping an Eye On" - Finviz
Jim Cramer on Insmed: “This One Is Worth Keeping an Eye On” - Insider Monkey
RBC Lifts Price Target on Insmed to $197 From $195, Keeps Outperform Rating - MarketScreener
Insmed price target raised to $231 from $223 at TD Cowen - MSN
How analysts rate Insmed Incorporated stock todayInterest Rate Changes & Affordable Trading Techniques - ulpravda.ru
Non-Cystic Fibrosis Bronchiectasis Market Growth to Surge During Forecast Period (2024–2034), Says DelveInsight | Insmed, AstraZeneca, Zambion, The Marcus Foundation, Chiesi Farmaceutici, SolAeroMed - Barchart.com
INSM stock up 78% in 6 months: Here's what you need to know - MSN
What Catalysts Are Quietly Shifting The Narrative For Insmed (INSM)? - Yahoo Finance
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib - The Motley Fool
Insmed Insider Sold Shares Worth $15,293,422, According to a Recent SEC Filing - marketscreener.com
INSM: UBS Lowers Price Target While Maintaining 'Buy' Rating | I - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed ... - Bluefield Daily Telegraph
UBS Adjusts Price Target on Insmed to $215 From $223, Maintains Buy Rating - MarketScreener
Insmed stock price target reiterated at $195 by Leerink on Brinsupri launch - Investing.com UK
INSM Stock Price, Forecast & Analysis | INSMED INC (NASDAQ:INSM) - Chartmill
Insmed Inc Azioni (INSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.47%
0.89%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):